Medical Treatments and Tofersen
Commons · Question 53047 · Tabled 19 May 2025 · Department of Health and Social Care · Official record
Answered 27 May 2025
Question
Asked by Jim Shannon
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of Early Access Programmes on equity of access to (a) tofersen and (b) other innovative treatments.
Answer
Answered by Karin Smyth, 27 May 2025
Early access schemes for unlicenced medicines, where approval may be obtained in other markets, including where a licence exists but a National Institute for Health and Care Excellence decision is not available, are managed by companies to benefit patient...